Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Michigan Medicine, MedImmune Partner in Diabetes and Metabolic Disease Research

By University of Michigan | March 9, 2017

 Michigan Medicine and MedImmune, the global biologics research and development arm of AstraZeneca (NYSE: AZN), have entered into a three-year research alliance to identify potential new therapies for the prevention and treatment of diabetes, obesity and related metabolic disorders.

The organizations are combining their research expertise to explore how the central nervous system and peripheral tissues rely on each other in these three major disease areas. In addition, researchers will develop and utilize cutting-edge technologies to study genetic models in order to understand and identify targets for the treatment of diabetes and related diseases.

“Creating new avenues for the exchange of innovative ideas and groundbreaking research among scientists from industry and academia is a critical part of drug discovery and development, and our partnership with Michigan Medicine is positioned to be living proof of that,” says Cristina Rondinone, head of Cardiovascular and Metabolic Diseases Innovative Medicines at MedImmune. “As the number of patients suffering from obesity continues to expand at an alarming rate, the need to identify new therapies is more important than ever. In working collaboratively with Michigan Medicine’s world-renowned metabolic scientists, we are creating an excellent team of researchers with potentially transformative implications for patients.”

Michigan Medicine experts in metabolism, gastroenterology and neuroendocrinology will collaborate with MedImmune on projects in the biotech’s existing Cardiovascular and Metabolic Diseases research portfolio.

“Every day, we’re making new connections between University of Michigan researchers and potential industry partners, facilitated by our Fast Forward Medical Innovation team,” notes Stephen Kunkel, Ph.D., senior associate dean for research at the University of Michigan Medical School. “With the ultimate goal of having a positive impact on patients, this collaboration with MedImmune is an opportunity for our researchers from multiple disciplines to work with a company whose strategies align with our deep strengths in diabetes and metabolic diseases.”

The Michigan Medicine team will be led by Martin Myers, M.D., Ph.D., professor of internal medicine and molecular and integrative physiology at Michigan Medicine, and director of the Michigan Diabetes Research and Training Center. The Michigan Medicine team includes fellow researchers Randy Seeley, Ph.D., Ormond MacDougald, Ph.D., Malcolm Low, M.D., Ph.D., and David Olson, M.D., Ph.D. The MedImmune team is headed by Chris Rhodes Ph.D., VP of CVMD Research, along with Joe Grimsby Ph.D and Jim Trevaskis Ph.D.


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE